NASDAQ:VTGN

Vistagen Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy VTGN

*Your capital is at risk

$0.241

+0 (+0%)

At Close: Jul 31, 2026

VistaGen Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 4.85M and sold 0 VTGN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	4.85M shares
● Sell	0 shares
100% Buy Activity Weak Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 24, 2024 Buy	Stock Option (Right to Buy) A-Award	Prince Joshua S. Chief Operating Officer	C-Suite Officer	150 000 Value: $484.5K
Jun 24, 2024 Buy	Stock Option (Right to Buy) A-Award	Prince Joshua S. Chief Operating Officer	C-Suite Officer	150 000 Value: $484.5K
Jun 24, 2024 Buy	Stock Option (Right to Buy) A-Award	Anderson Cynthia Lynn Chief Financial Officer	C-Suite Officer	150 000 Value: $484.5K
Jun 24, 2024 Buy	Stock Option (Right to Buy) A-Award	Adler Reid G. Chf Corp Devel Off, Gen Couns	Officer	170 000 Value: $549.1K
Jun 24, 2024 Buy	Stock Option (Right to Buy) A-Award	Singh Shawn Chief Executive Officer	CEO / President	500 000 Value: $1.62M
Mar 04, 2024 Buy	Stock Option (Right to Buy) A-Award	Rotunno Mary L. Director	Director	12 500 Value: $60.6K
Mar 04, 2024 Buy	Stock Option (Right to Buy) A-Award	Gin Jerry B Director	Director	12 500 Value: $60.6K
Mar 04, 2024 Buy	Stock Option (Right to Buy) A-Award	Fitzpatrick Margaret M Director	Director	12 500 Value: $60.6K
Mar 04, 2024 Buy	Stock Option (Right to Buy) A-Award	Curley Joanne Director	Director	12 500 Value: $60.6K
Mar 04, 2024 Buy	Stock Option (Right to Buy) A-Award	Cunningham Ann Michelle Director	Director	12 500 Value: $60.6K
Mar 04, 2024 Buy	Stock Option (Right to Buy) A-Award	Saxe Jon S Director	Director	12 500 Value: $60.6K
Mar 04, 2024 Buy	Stock Option (Right to Buy) A-Award	Saxe Jon S Director	Director	12 500 Value: $60.6K
Mar 04, 2024 Buy	Stock Option (Right to Buy) A-Award	Cunningham Ann Michelle Director	Director	12 500 Value: $60.6K
Mar 04, 2024 Buy	Stock Option (Right to Buy) A-Award	Curley Joanne Director	Director	12 500 Value: $60.6K
Mar 04, 2024 Buy	Stock Option (Right to Buy) A-Award	Fitzpatrick Margaret M Director	Director	12 500 Value: $60.6K
Mar 04, 2024 Buy	Stock Option (Right to Buy) A-Award	Gin Jerry B Director	Director	12 500 Value: $60.6K
Mar 04, 2024 Buy	Stock Option (Right to Buy) A-Award	Rotunno Mary L. Director	Director	12 500 Value: $60.6K
Dec 29, 2023 Buy	Common Stock A-Award	Adler Reid G. Chf Corp Devel Off, Gen Couns	Officer	167 Value: $287
Dec 29, 2023 Buy	Common Stock A-Award	Singh Shawn Chief Executive Officer	CEO / President	167 Value: $287
Dec 29, 2023 Buy	Common Stock A-Award	Singh Shawn Chief Executive Officer	CEO / President	167 Value: $287
Dec 29, 2023 Buy	Common Stock A-Award	Adler Reid G. Chf Corp Devel Off, Gen Couns	Officer	167 Value: $287
Oct 24, 2023 Buy	Stock Options (Right to buy)	Prince Joshua S. Chief Operating Officer	C-Suite Officer	3 334 Value: $137.0K
Oct 24, 2023 Buy	Stock Options (Right to buy)	Prince Joshua S. Chief Operating Officer	C-Suite Officer	5 000 Value: $322.5K
Oct 24, 2023 Buy	Stock Options (Right to buy)	Prince Joshua S. Chief Operating Officer	C-Suite Officer	5 001 Value: $22.2K
Oct 24, 2023 Buy	Stock Options (Right to buy)	Prince Joshua S. Chief Operating Officer	C-Suite Officer	5 000 Value: $322.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT VISTAGEN THERAPEUTICS INC

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product...

Read Full Profile Here